Alto Neuroscience, Inc.
ANRO
$3.43
$0.020.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.23% | -48.88% | -69.21% | -75.46% | -- |
| Total Depreciation and Amortization | 64.16% | 50.00% | 34.58% | 24.02% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.80% | 94.26% | 196.83% | 161.66% | -- |
| Change in Net Operating Assets | -156.15% | -1,595.65% | 681.66% | 119.83% | -- |
| Cash from Operations | -31.25% | -43.60% | -41.78% | -64.35% | -- |
| Capital Expenditure | -60.06% | -178.60% | -341.49% | -967.22% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -60.06% | -178.60% | -341.49% | -967.22% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.77% | -99.73% | 76,013.81% | 88,198.72% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 28.42% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 101.27% | 83.45% | -62.12% | -1,177.17% | -- |
| Cash from Financing | -93.74% | -94.23% | 99.16% | 299.85% | -- |
| Foreign Exchange rate Adjustments | -316.67% | -566.67% | -37.50% | -262.50% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -133.83% | -131.86% | 151.96% | 688.97% | -- |